ArticleFrontiers in immunology2022
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Immunotherapy targeting drug-tolerant Mycobacterium tuberculosis persisters accelerates tuberculosis cure in preclinical models.The Journal of clinical investigation · 2026Article
- Enantiomer-dependent and modification-free DNA matrix as an adjuvant for subunit vaccines against SARS-CoV-2 or pneumococcal infections.Nature biomedical engineering · 2025Article
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- MIP3α-RelVaccine · 2025Article
- MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.Scientific reports · 2025Article
- Mucosal immunotherapy targeting APC in lung disease.Journal of inflammation (London, England) · 2025Review
- Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models.Vaccines · 2025Article
- Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model.Frontiers in immunology · 2025Article
- Article
- A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses.Frontiers in immunology · 2024Article
- An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Styliani KaranikaDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
James T GordyCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Pranita NeupaneDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Theodoros KarantanosDivision of Hematological Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, MD, United States.
Jennie Ruelas CastilloDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Darla QuijadaDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Kaitlyn ComstockCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Avinaash K SandhuCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Aakanksha R KapoorDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Yinan HuiCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Samuel K AyehDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Rokeya TasneenDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Stefanie KrugDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Carina DanchikDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Tianyin WangCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Courtney SchillCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Richard B MarkhamCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Petros C KarakousisDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States.
Johns Hopkins Medicine · USJohns Hopkins University · USJohns Hopkins Hospital · US
Funding
RESEARCH TRAINING IN MICROBIAL DISEASEST32AI007291 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JOEL N BLANKSON, Sara Elizabeth Cosgrove · 1986 to 2026
$9.1MPharmacology and Pharmacometrics CoreP30AI168436 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JONATHAN E. GOLUB · 2022 to 2026
$6.1MTherapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persistersR01AI148710 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C, MARKHAM, RICHARD B. · 2020 to 2024
$3.8MMentoring in Immunometabolic Dysregulation in TB and TB/HIVK24AI143447 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2019 to 2024
$956kImmunotherapy Targeting MTB Persisters in the DC-impaired Setting of HIV and TBR21AI140860 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C, MARKHAM, RICHARD B. · 2018 to 2019
$450kNIAID NIH HHS K24 AI143447NIAID NIH HHS P30 AI168436NIAID NIH HHS R01 AI148710NIAID NIH HHS R21 AI140860NIAID NIH HHS T32 AI007291
Abstract
Lengthy tuberculosis (TB) treatment is required to overcome the ability of a subpopulation of persistent
Indexed as
TuberculosisVaccines, DNAAnimalsAnti-Bacterial AgentsDendritic CellsIsoniazidMiceAnti-Bacterial AgentsIsoniazidVaccines, DNAimmunotherapyintranasal routeMycobacterium tuberculosispersistencestringent responseT cellstuberculosis DNA vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.